WaveBreak
Sarah Ball, a Senior Scientist at WaveBreak (formerly Wren Therapeutics), has a strong background in research and academia. Sarah previously worked as a Research Assistant at Amgen and Academic Tutor at the University of Sydney. Sarah holds a Ph.D. in Medicine from the University of Sydney, where Sarah also obtained a Bachelor of Medical Science (Honors) degree in Pharmacology/Neuroscience.
This person is not in any offices
WaveBreak
WaveBreak is a biopharmaceutical company focused on transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS.